Back to Search Start Over

National Institutes of Health Stroke Scale: An Alternative Primary Outcome Measure for Trials of Acute Treatment for Ischemic Stroke

Authors :
Chalos, V. (Vicky)
Ende, N.A.M. (Nadina) van der
Lingsma, H.F. (Hester)
Mulder, M.J.H.L. (Maxim)
Venema, E. (Esmee)
Dijkland, S.A. (Simone)
Berkhemer, O.A. (Olvert)
Yoo, A.J. (Albert J.)
Broderick, J.P. (Joseph P.)
Palesch, Y.Y. (Yuko Y.)
Yeatts, S.D. (Sharon D.)
Roos, Y.B.W.E.M. (Yvo)
Oostenbrugge, R.J. (Robert) van
Zwam, W.H. (Wim) van
Majoie, C.B.L.M. (Charles B L M)
Lugt, A. (Aad) van der
Roozenbeek, B. (Bob)
Dippel, D.W.J. (Diederik)
Chalos, V. (Vicky)
Ende, N.A.M. (Nadina) van der
Lingsma, H.F. (Hester)
Mulder, M.J.H.L. (Maxim)
Venema, E. (Esmee)
Dijkland, S.A. (Simone)
Berkhemer, O.A. (Olvert)
Yoo, A.J. (Albert J.)
Broderick, J.P. (Joseph P.)
Palesch, Y.Y. (Yuko Y.)
Yeatts, S.D. (Sharon D.)
Roos, Y.B.W.E.M. (Yvo)
Oostenbrugge, R.J. (Robert) van
Zwam, W.H. (Wim) van
Majoie, C.B.L.M. (Charles B L M)
Lugt, A. (Aad) van der
Roozenbeek, B. (Bob)
Dippel, D.W.J. (Diederik)
Publication Year :
2020

Abstract

Background and Purpose- The modified Rankin Scale (mRS) at 3 months is the most commonly used primary outcome measure in stroke treatment trials, but it lacks specificity and requires long-term follow-up interviews, which consume time and resources. An alternative may be the National Institutes of Health Stroke Scale (NIHSS), early after stroke. Our aim was to evaluate whether the NIHSS assessed within 1 week after treatment could serve as a primary outcome measure for trials of acute treatment for ischemic stroke. Methods- We used data from 2 randomized controlled trials of endovascular treatment for ischemic stroke: the positive MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; N=500) and the neutral IMS (Interventional Management of Stroke) III trial (N=656). We used a causal mediation model, with linear and ordinal logistic regression adjusted for confounders, to evaluate the NIHSS 24 hours and 5 to 7 days after endovascular treatment as primary outcome measures (instead of the mRS at 3 months) in both trials. Patients who had died before the NIHSS was assessed received the maximum score of 42. NIHSS+1 was then log10-transformed. Results- In both trials, there was a significant correlation between the NIHSS at 24 hours and 5 to 7 days and the mRS. In MR CLEAN, we found a significant effect of endovascular treatment on the mRS and on the NIHSS at 24 hours and 5 to 7 days. After adjustment for NIHSS at 24 hours and 5 to 7 days, the effect of endovascular treatment on the mRS decreased from common odds ratio 1.68 (95% CI, 1.22-2.32) to respectively 1.36 (95% CI, 0.97-1.91) and 1.24 (95% CI, 0.87-1.79), indicating that treatment effect on the mRS is in large part mediated by the NIHSS. In the IMS III trial there was no treatment effect on the NIHSS at 24 hours and 5 to 7 days, corresponding with the absence of a treatment effect on the mRS. Conclusions- The NIHSS within 1 week satisfies the requir

Details

Database :
OAIster
Notes :
application/pdf, Stroke vol. 51 no. 1, pp. 282-290, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1143371813
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1161.STROKEAHA.119.026791